2109805-75-4
基本信息
Spiro[2H-1-benzopyran-2,4'-[4H]pyran], 2',3',5',6'-tetrahydro-6,7-bis[(4-nitrophenyl)methoxy]-
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/08/19 | HY-101929 | 2109805-75-4 CU-CPT17e | 2109805-75-4 | 1mg | 2100元 |
2024/08/19 | HY-101929 | 2109805-75-4 CU-CPT17e | 2109805-75-4 | 5mg | 4400元 |
2024/08/19 | HY-101929 | 2109805-75-4 CU-CPT17e | 2109805-75-4 | 10mg | 6600元 |
常見問題列表
TLR3
|
TLR8
|
TLR9
|
CU-CPT17e shows strong NF-κB activation in TLR3, TLR8 and TLR9 HEK293 cells with EC 50 values of 4.80±0.73, 13.5±0.58 and 5.66±0.17 μM, respectively. CU-CPT17e significantly improves the activity with 13.9±0.9 fold of NF-κB activation and an EC 50 value of 4.8±0.7 μM. CU-CPT17e inhibits the proliferation of HeLa cancer cells by triggering apoptosis and arresting the cell cycle at the S phase. The induction of apoptosis by CU-CPT17e in HeLa cells is investigated. HeLa cells are cultured with increasing concentrations of CU-CPT17e or poly I:C or blank control (DMSO) for 24 h. Treatment with CU-CPT17e for 24 h at different concentrations (10 to 40 μM) results in an elevation of apoptotic cell population ranging from 10% to 17%, which is more effective than poly I:C at 5 μg/mL. These results suggest that the antiproliferative activity of CU-CPT17e against HeLa cells might result from its ability to directly induce apoptosis.